Cannabidiol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Cannabidiol for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Cannabidiol is the non-intoxicating fraction of cannabis, sold as oils, capsules and creams for sleep, pain and stress. Repeated controlled testing establishes only two effects: lower around-the-clock blood pressure where pressure is raised, and fewer seizures in rare childhood epilepsies at doses far above consumer products. Anxiety, sleep, pain and recovery claims point both ways. Liver enzyme rises and raised blood levels of other medicines are the main harms. (Full Review)

Protocol

Consumer oral protocol
15–50 mg daily
Oil or softgel. Sustained-use trials in adults have generally used 150–300 mg daily
Best time of day
Split or evening
Split twice-daily dosing was used in every pivotal trial; single evening dosing suits sleep or evening anxiety
Baseline biomarkers
Liver panel, blood pressure
Established before the first dose. A normal ALT permits a standard titration; a raised one argues against use
Time to effect
Blood Pressure
2.5 weeks
Reductions were measurable within 2.5 weeks; steady state takes about a week to reach
Acute Calming
60–90 minutes
Appears after an oral dose
Sleep and Pain
2–4 weeks
Where present, in the trials that found them

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Baseline ALT or AST above three times the upper limit of normal
  • Child-Pugh Class B or C liver impairment
  • Valproate users whose ALT or AST already exceeds twice the upper limit of normal
  • Solid-organ transplant recipients on tacrolimus, sirolimus or everolimus without transplant-clinic supervision
  • Anyone subject to zero-tolerance workplace or competitive drug testing who cannot verify a product's tetrahydrocannabinol content by batch
  • Children and adolescents outside the approved seizure indications
    •
Key Interactions
  • Valproate (antiseizure drug)
  • Clobazam and other benzodiazepines (sedative drugs)
  • Warfarin and other CYP2C9 substrates
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)
  • CYP3A4 inducers (rifampicin, carbamazepine, St John's wort)
  • Caffeine and other CYP1A2 substrates
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) and alcohol
  • Sedating supplements (melatonin, valerian, kava, magnesium at high dose)
  • Blood-pressure-lowering supplements (beetroot or dietary nitrate, garlic extract, hibiscus, potassium)
  • Other cannabinoids (delta-9-tetrahydrocannabinol, cannabigerol, delta-8-tetrahydrocannabinol)
  • High-fat meals
    •

Risk & Side Effects

  • High: Elevated liver enzymes and drug-induced liver injury; diarrhoea and vomiting; somnolence, sedation and fatigue; decreased appetite and weight loss; raised blood levels of co-administered medicines; asymptomatic shifts in haemoglobin and serum creatinine; rash and hypersensitivity reactions
  • Medium: Unintended tetrahydrocannabinol exposure and positive cannabis drug tests
  • Low: Additive lowering of blood pressure; sleep disturbance and next-day alertness effects; suicidal thoughts and behaviour
  • Speculative: Suppression of androgen production; harm to a developing fetus or nursing infant

Monitoring

Marker Target Why
ALT (alanine aminotransferase) 10–26 U/L (men), 8–22 U/L (women) Detects the main documented harm early
AST (aspartate aminotransferase) 10–26 U/L Separates liver from muscle origin when ALT rises
Total bilirubin 0.3–1.0 mg/dL Distinguishes an enzyme blip from genuine impaired liver function
GGT 10–20 U/L Confirms a liver rather than incidental source of enzyme rise
Home blood pressure 110–125 / 70–80 mmHg Captures the best-supported benefit and the additive-hypotension risk
Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women) Detects the fall seen in the prescription trial programme
eGFR Above 90 mL/min/1.73 m² Interprets the creatinine rise seen within two weeks of starting
hs-CRP Below 1.0 mg/L Tracks the claimed anti-inflammatory effect, which is unproven in humans
Drug level of any interacting prescription The established therapeutic range for that specific drug Catches the silent dose increase that drives most reported harm

Cadence: Liver panel and blood pressure at baseline; liver panel repeated at 1, 3 and 6 months, then every 6–12 months while use continues. Blood pressure daily for the first two weeks of any dose increase, then monthly. Drug levels within 2 weeks of starting or changing dose.

Qualitative Assessment

  • Anxiety in a specific recurring situation, rated 0–10 in the same context each time rather than as a general impression
  • Time to fall asleep and number of night wakings, recorded nightly rather than recalled weekly
  • Next-morning sedation, which distinguishes an effective evening dose from an excessive one
  • Appetite and body weight, since suppression is common and unwanted at this stage of life
  • Stool frequency and consistency, the earliest sign that the dose or the carrier oil needs changing
  • Pain in one named joint, rated on the same scale, rather than a global sense of feeling better
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.